Cassava Sciences, Inc. (SAVA): Price and Financial Metrics


Cassava Sciences, Inc. (SAVA): $28.80

0.80 (+2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SAVA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SAVA Stock Price Chart Interactive Chart >

Price chart for SAVA

SAVA Price/Volume Stats

Current price $28.80 52-week high $62.49
Prev. close $28.00 52-week low $13.84
Day low $27.30 Volume 1,102,900
Day high $29.09 Avg. volume 1,949,419
50-day MA $33.47 Dividend yield N/A
200-day MA $29.56 Market Cap 1.15B

Cassava Sciences, Inc. (SAVA) Company Bio


Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.


SAVA Latest News Stream


Event/Time News Detail
Loading, please wait...

SAVA Latest Social Stream


Loading social stream, please wait...

View Full SAVA Social Stream

Latest SAVA News From Around the Web

Below are the latest news stories about CASSAVA SCIENCES INC that investors may wish to consider to help them evaluate SAVA as an investment opportunity.

Why Is Cassava Sciences (SAVA) Stock Down 20% Today?

Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall.

Chris MacDonald on InvestorPlace | January 24, 2023

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors

Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage.

Yahoo | January 24, 2023

Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results

Editor's note: The headline of this story has been updated to more accurately reflect the results of the Cassava Sciences Phase 2 trial for simufilam. Cassava Sciences Inc (NASDAQ: SAVA) announced topline Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. Study participants were administered open-label simufilam tablets 100mg twice daily for one year or more. Endpoints were measured at baseline (study entry) and month 12. In the mild sub-group, ADAS-Cog (cog

Yahoo | January 24, 2023

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point

Yahoo | January 24, 2023

Cassava Sciences Stock Shows Big Jump In Its Relative Strength Rating

Cassava Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 87.

Yahoo | January 18, 2023

Read More 'SAVA' Stories Here

SAVA Price Returns

1-mo 3.75%
3-mo -18.34%
6-mo 64.57%
1-year -37.02%
3-year 254.68%
5-year 357.14%
YTD -2.51%
2022 -32.40%
2021 540.76%
2020 31.15%
2019 511.76%
2018 -78.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6167 seconds.